89bio — Company Overview, News & Financial Data

89bio (NASDAQ:ETNB) is a biopharmaceutical company deeply engaged in the development and innovation of therapies targeting liver and cardio-metabolic diseases. With a robust focus on creating solutions for nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and other disorders, 89bio is dedicated to addressing unmet medical needs through a pipeline of potentially groundbreaking treatments. Their lead product candidate, pegozafermin, represents a significant part of their commitment to advancing healthcare and improving patient outcomes. The objective of 89bio is to pioneer effective and safer treatments that can greatly enhance the quality of life for individuals suffering from these chronic conditions, emphasizing their dedication to scientific excellence and patient well-being.